Swedencare AB (publ) (SECARE) Earnings Call Transcripts
Swedencare AB (publ)'s Latest Earnings Call - June 17, 2026
In the Q2 update for fiscal year 2026, Swedencare AB highlighted ongoing challenges but also positive developments, particularly in online sales and new market expansions. Revenue growth is expected to remain in double digits, with management maintaining a gross margin target of 58%-59%. The company anticipates improved profitability in Q3, following a challenging first half due to supply chain issues and distributor mergers affecting veterinary sales. Overall, the sentiment is cautiously optimistic as the company navigates these transitions.
Reported metrics
| Metric | Value |
|---|---|
| Revenue Growth | double-digit organic growth (positive) |
| Gross Margin | 58%-59% (inline) |
| EBITDA Margin | 19.6% (positive) |
| Net Debt to EBITDA | 2.8 (inline) |
| Veterinary Sales Exposure | $20M-$30M (negative) |
| Amazon Sales Normalization | early to mid-Q3 (positive) |
Guidance from management
Management expects improved profitability in Q3, with no material one-offs anticipated. They maintain a gross margin target of 58%-59% for the quarter.
What management said
Welcome to Swedencare's pre-quarter update, where Jenny and Hakan will provide a short presentation, followed by a Q&A. So please raise your hand if you have any questions. Over to you, Jenny and Hakan.
It's difficult to say because we also sell products to -- we manufacture products to brands that sell to them. So it's a very complex lots -- I mean, we have many products ending up in these sales channels. But direct sales for us on a yearly basis, I would say that it's between 20 million to -- I don't have the exact number, so USD 20 million, USD 30 million. That's my best guess, but don't hold me to it.
What analysts pressed on
Analysts expressed concerns about the impact of the distributor merger on veterinary sales, with questions about how structural changes could affect overall market dynamics. There is uncertainty regarding inventory levels and order changes during this transition.
Main topics on the call
- Revenue Growth Expectations — Management expects 'double-digit organic growth for the quarter', indicating confidence in sales performance despite recent challenges. This growth is supported by new market entries and increased online sales.
- Impact of Distributor Mergers — The merger of the two largest U.S. distributors, controlling over 60% of the market, is causing uncertainty. Hakan Lagerberg noted that 'how they will organize, we don't know as of yet', indicating potential disruptions ...
- Amazon Sales Normalization — Management indicated that issues with Amazon sales are expected to normalize by 'early to mid-Q3', which is crucial for recovery in online sales. This follows a challenging first half due to transparency issues.
- Gross Margin Stability — The company aims to maintain gross margins between 58% and 59%, consistent with previous quarters. Jenny Graflind stated, 'we expect to stay there for this quarter', which reflects stability amid inflationary pressures.
Read the full Swedencare AB (publ) transcript (June 17, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Swedencare AB (publ)
Swedencare AB (publ) (SECARE) is a publicly listed company in the Pharmaceuticals industry, within the Health Care sector. It trades on OM and is based in SE. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 21 calls on record spanning February 17, 2022 to July 22, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 21 Swedencare AB (publ) earnings call transcripts on record, spanning February 17, 2022 to July 22, 2026. Based on this history, Swedencare AB (publ) reports quarterly. The most recent call on file is dated July 22, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- SECARE
- Exchange
- OM
- Country
- SE
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Calls on record
- 21
- First call
- February 17, 2022
- Most recent
- July 22, 2026
- Reporting cadence
- quarterly
| Quarter | Date | |
|---|---|---|
| Earnings Calls | Jul 22, 2026 | Read transcript → |
| Shareholder/Analyst Calls | Jun 17, 2026 | Read transcript → |
| Analyst/Investor Day | Jun 2, 2026 | Read transcript → |
| Q1 FY2026 | Apr 23, 2026 | Read transcript → |
| Shareholder/Analyst Calls | Mar 20, 2026 | Read transcript → |
| Earnings Calls | Feb 12, 2026 | Read transcript → |
| Q3 FY2025 | Oct 22, 2025 | Read transcript → |
| Q1 FY2025 | Apr 24, 2025 | Read transcript → |
| Earnings Calls | Feb 13, 2025 | Read transcript → |
| Q3 FY2024 | Oct 23, 2024 | Read transcript → |
| Earnings Calls | Jul 25, 2024 | Read transcript → |
| Q1 FY2024 | Apr 25, 2024 | Read transcript → |
| Earnings Calls | Feb 15, 2024 | Read transcript → |
| Q3 FY2023 | Oct 25, 2023 | Read transcript → |
| Earnings Calls | Jul 27, 2023 | Read transcript → |
| Q1 FY2023 | Apr 28, 2023 | Read transcript → |
| Earnings Calls | Feb 16, 2023 | Read transcript → |
| Q3 FY2022 | Oct 27, 2022 | Read transcript → |
| Q2 FY2022 | Jul 28, 2022 | Read transcript → |
| Q1 FY2022 | May 12, 2022 | Read transcript → |
| Earnings Calls | Feb 17, 2022 | Read transcript → |